1. Introduction {#sec1}
===============

Fibromyalgia syndrome (FMS) is a rheumatologic neuropathic chronic pain syndrome affecting approximately 2.7% of populations of all ages across the world \[[@B1]\], including an estimated 1.8--6.4% of those in the US \[[@B2], [@B3]\]. FMS is characterized by a constellation of somatic symptoms (e.g., fatigue, sleep, mood disturbances, and cognitive impairment) that are typically present in addition to widespread pain \[[@B4]\]; the etiology of FMS is largely unknown \[[@B4]\]. Additionally, those with FMS may also experience high rates of comorbidity, such as osteoarthritis \[[@B5]\], autoimmune \[[@B6]\], kidney \[[@B7]\], respiratory \[[@B7]\], and cardiovascular \[[@B7], [@B8]\] disease, gastrointestinal conditions \[[@B7], [@B9]\], and headache \[[@B1], [@B7], [@B10]\]. Although FMS affects both sexes and people of all ages, the majority of US cases occur in Caucasian, middle-aged women \[[@B11], [@B12]\].

The chronic widespread pain characterizing FMS is difficult to manage, and many physicians remain unfamiliar with FMS diagnostic criteria and treatment \[[@B13]\] often making it difficult for patients to obtain an accurate FMS diagnosis and appropriate care. Although a lack of efficacy evidence for opioids as FMS treatment exists \[[@B14], [@B15]\] and opioid overdose deaths have more than tripled since 1999 \[[@B16], [@B17]\], FMS patients may receive opioid therapy \[[@B18]\]. Common treatments for FMS include antidepressants, anticonvulsants, muscle relaxants, and other pain medications \[[@B19]\]. Nonsteroidal anti-inflammatory drugs, which may carry side effects for as many as 25% of long-term users \[[@B20]\], are not currently recommended for FMS by any guidelines \[[@B19]\]. Although three drugs are FDA-approved for FMS treatment \[[@B21]\], these medications may carry significant side effects for some \[[@B22]\] and are not always effective for all \[[@B19]\]. Thus, patients may turn to complementary health approaches (CHAs, defined as medical/healthcare systems or practices used outside of mainstream medicine \[[@B23]\]) to manage symptoms \[[@B24]\]; back, neck, and joint pain are among the most commonly reported conditions for which patients use CHAs in the US \[[@B25], [@B26]\].

Nonvitamin, nonmineral dietary supplements (NVNMs) are a type of CHA used by nearly twenty-five percent of US adults with a musculoskeletal disorder \[[@B25]\] and include animal- and plant-derived products (i.e., fish oil, herbal dietary supplements). The extent and efficacy of NVNMs, particularly herbal dietary supplements, are largely unknown \[[@B27], [@B28]\]. Although a handful of large surveys have documented high rates of herbal and other NVNM use for chronic pain syndromes \[[@B24], [@B25], [@B29], [@B30]\], and anecdotal accounts indicate that a wide range of herbs have been used for the treatment of FMS \[[@B31]\], rigorous investigations regarding the prevalence and correlates of NVNM use in FMS remain limited. To address these gaps, we assessed the relation of FMS to NVNM use in two large, representative samples of US adults and examined potential changes in prevalence rates for NVNM use among those with FMS over a 5-year time period.

2. Materials and Methods {#sec2}
========================

2.1. Data Sources {#sec2.1}
-----------------

Participants for this study were drawn from two nationally representative samples of 23,501 and 34,525 US adults (National Health Interview Surveys (NHIS), 2007 and 2012, resp.). The NHIS is an annual national, cross-sectional household survey of the noninstitutionalized US population and is administered by the Centers for Disease Control and Prevention\'s National Center for Health Statistics. A supplement (adult alternative medicine) to the core individual, family, and household surveys asked participants about use of a broad range of CHAs, including herbs and other NVNMs, for both years. All questions were administered in a personal interview format. Adult response rates to the NHIS were 78.3% in 2007 and 79.7% in 2012, respectively \[[@B32]\].

The NHIS is the only national, public-use survey that includes comprehensive sets of questions regarding NVNM and other CHA use. Both 2007 and 2012 surveys used a stratified multistage probability design weighted on age, sex, and race/ethnicity, using 2000 and 2010 Census data for each, respectively. Both surveys oversampled Asian, Black, Hispanic, and minority elderly populations. Thus, each person in the covered population had a known nonzero probability of selection. Additional project details have been described elsewhere \[[@B32]\].

2.2. Study Population {#sec2.2}
---------------------

Our analysis excluded participants who were \<18 years of age, were pregnant, had functional limitation(s) due to senility, had a stroke and used a proxy to complete the interview, or had current cancer; those missing data on key covariates were also excluded, as were participants with extreme values for exercise (\>6,000 minutes per week) in order to eliminate potential information bias. Further exclusion of persons with missing data on FMS and NVNM use (at 30 days, at 12 months, or ever using NVNMs) yielded final study samples of 20,127 and 30,672 adults for 2007 and 2012, respectively ([Figure 1](#fig1){ref-type="fig"}).

2.3. Variables {#sec2.3}
--------------

### 2.3.1. Outcome Variables {#sec2.3.1}

The main outcome variable for this study was the reported use of NVNMs within the past 12 months (Y/N). We additionally assessed use of NVNMs within the previous 30 days (Y/N) and ever (Y/N). Briefly, survey participants were shown a card with a list of NVNMs (for which the majority were comprised of herbs or their compounds; 2007 list: 44 NVNM items with additional queries for up to two combination supplements, and 2012 list: 21 NVNM items with additional queries for up to two combination supplements) and queried for a dichotomous response regarding consumption of any "herbal or other nonvitamin supplements." NVNMs included those labelled "dietary supplement" and in the form of pills, capsules, tablets, or (2012) liquids (including tinctures) and did not include homeopathic or cannabis products.

### 2.3.2. Exposure Variable {#sec2.3.2}

Our main exposure was fibromyalgia syndrome (FMS) (Y/N), ascertained as an affirmative response to fibromyalgia after being asked "Have you EVER been told by a doctor or other health professional that you had some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia? Which of these were you told you had?"

### 2.3.3. Covariates {#sec2.3.3}

Demographics, lifestyle factors, health conditions, and medical care-related factors known or suspected to be associated with CHAs, NVNM use, and/or FMS were considered a priori as potential covariates in multivariate models. Demographic factors assessed included age, gender, race/ethnicity, education, employment, income, marital status, geographic region, and place of birth. Additional related factors included insurance status, annual family out-of-pocket medical costs, and delay of care due to concerns over cost. Lifestyle factors included smoking status, alcohol use, exercise, BMI (using the National Institutes of Health clinical classifications scores) \[[@B33]\], health status, and substance abuse. Health conditions included self-reported history of physician-diagnosed diabetes, kidney disease, gastrointestinal disorder, respiratory conditions, dyslipidemia, liver condition, rheumatoid arthritis, cardiovascular disease, hypertension, nonspecific arthritis, gout, migraines, mental health condition, insomnia, and previous cancer diagnosis. These variables are described in greater detail below.

2.4. Statistical Analysis {#sec2.4}
-------------------------

We conducted complete-case analyses using SAS 9.4 (Cary, NC, USA) and used sampling weights to account for complex survey procedures; these were adjusted for the probabilities of selection, nonresponse, and poststratification \[[@B34]\]. We merged NHIS family, person, household, sample adult, and adult alternative health files for each year and measured sample characteristics, including frequencies/prevalence rates of NVNM use (previous or current use, past 12 months, and past 30 days) for 2007 and 2012, respectively; we extrapolated estimates to generate population frequencies using NHIS sampling weights. Weighted *t*-tests and Rao-Scott Chi-square tests were used to determine significant differences by NVNM use status for three outcome time points in both survey years; significant factors were included in models as covariates. We also used a DOMAIN statement to keep our exclusions separate while maintaining the integrity of sampling weights and used Chi-square and *t*-tests to determine significant changes between 2007 and 2012 on weighted frequencies and means of all items, in addition to number of different NVNMs used, physician disclosure of NVNM use, and use of other CHAs. We considered trends between time points significant if there was no overlap in weighted percentage confidence intervals. Differences between participants with versus without missing data were assessed. All *p* values shown are two-sided at *p* ≤ 0.05.

Weighted logistic regressions were used to evaluate the independent associations of FMS diagnosis to NVNM use in the last 30 days or 12 months or ever. All multivariate models were adjusted for demographics and medical care-related factors; additional models also included lifestyle characteristics and health conditions.

Demographic characteristics included age (evaluated as both a continuous and categorical variable (18--24, 25--44, 45--64, 65--74, and 75+ years)), sex (male/female), race ("non-Hispanic White," "non-Hispanic Black," "Hispanic," "Asian," and "other"), marital status ("married/cohabitating," "divorced/separated/widowed," and "single"), education ("≤some HS," "HS/GED," "some college/AA/tech," and "bachelor\'s degree+"), employment ("employed for pay," "employed but not for pay," and "unemployed"), income (\$1--\$24,999; \$25,000--\$44,999; \$45,000--\$74,999; \$75,000+; "do not know;" and "missing"), geographic region ("northeast," "midwest," "south," and "west"), and place of birth (US-born/other). Medical care-related factors included insurance status ("uninsured," "Medicaid," "Medicare," "disability," and "private"), annual out-of-pocket medical costs ("none"; \<\$500; \$500--\$1999; \$2000--\$2999; \$3000--\$4999; \$5000 and over; and "do not know"), and delayed access to care because they "could not afford" or "worried about cost" (yes/no). Additional analyses also controlled for lifestyle-related factors, including BMI (evaluated as continuous and categorical (\<18.5 = "underweight," 18.5--25 = "underweight or normal weight," 25--29.9 = "overweight," 30--34.9 = "obese class 1," and 35+ = "obese classes 2/3")) \[[@B35]\]; tobacco use ("current smoker," "former smoker," and "never smoked"); alcohol use ("none," "light," and "moderate to heavy"); substance abuse other than tobacco or alcohol in past year (yes/no); and physical activity (continuous, in minutes/week).

In our fully adjusted models, we also evaluated the potentially confounding influence of self-reported health status ("excellent/very good/good," "fair," and "poor"), specific health conditions, and total number of health conditions; this comorbidity index was created from 0--13 participant-reported conditions, including a history of (1) diabetes; (2) kidney disease; (3) gastrointestinal disorder (including history of ulcers, inflammatory/irritable bowel disease, or constipation severe enough to require medication in the past year and/or (2012) abdominal pain, digestive allergy, and/or heartburn in the past year); (4) respiratory conditions (history of asthma or emphysema and/or chronic bronchitis); (5) dyslipidemia; (6) liver condition; (7) rheumatoid arthritis; (8) cardiovascular disease (coronary heart disease, angina, and/or heart attack); (9) hypertension; (10) nonspecific arthritis; (11) gout; (12) migraines; and (13) mental health condition (depression, phobias, and/or being often anxious in past year and/or ever having bipolar disorder). Health conditions were evaluated both collectively and individually; insomnia in the past year and previous cancer diagnosis were evaluated individually.

We also assessed the potential modifying influence of gender and presence of comorbid health conditions (0-1 versus 2+) on the association between FMS and NVNM use at each outcome time point and for each survey year by including the corresponding multiplicative-interaction term in age-adjusted models.

3. Results and Discussion {#sec3}
=========================

Relative to participants with complete data in both survey years, those with missing data on key covariates were less likely to be employed and report high educational attainment and more likely to be underweight, be older, and indicate poor reported health status (*p*\'s ≤ 0.0001). Participant age ranged from 18 to 85 years, averaging 47.5 ± 0.25 and 48.5 ± 0.18 years for 2007 and 2012, respectively. In both years, study participants were predominantly white (72.2% and 69.5%, resp.), female (53.1% and 53.5%), and insured (84.3% and 84.2%); most (56.4% and 57.9%) reported they never smoked cigarettes. Excluding prayer, most participants had used at least one CHA before (69.8% and 68.8%), and a majority had also used natural products other than NVNMs (60.4% and 62.4%) (not shown). In both years, 35% were overweight (mean BMI = 27.4 ± 0.05 and 27.7 ± 0.04, for 2007 and 2012, resp.), and most (63% and 72%) reported at least one chronic health condition, with the number of chronic health conditions increasing from a mean of 1.5 ± 0.02 in 2007 to 1.9 ± 0.01 in 2012.

[Table 1](#tab1){ref-type="table"} illustrates the distribution of demographic and lifestyle characteristics, stratified by year and NVNM use in the past 12 months; medical-related/health characteristics are displayed in [Table 2](#tab2){ref-type="table"}. The percentage of adults reporting NVNM use (ever) declined significantly between time points (*p* \< 0.0001) from 27.1% of the sample population in 2007 (*n* = 5057) to 24.2% in 2012 (*n* = 7238; not shown). In contrast, the percentage of adults reporting use of NVNMs within the last 12 months (19.1% to 18.5%, resp.) and 30 days (13.9% in both years; not shown) remained approximately the same. Prevalence of diagnosed FMS also increased from 1.3% to 1.7% (*p* \< 0.0001) ([Table 3](#tab3){ref-type="table"}). Consistent with a slight decrease in overall NVNM use among the general population, overall NVNM use among adults diagnosed with FMS declined from 57% in 2007 to 41% in 2012 (*p* \< 0.0001). There were no apparent changes in the number of different combination NVNM supplements taken among those with FMS (mean (SE) for past 30 days = 0.99 (0.20) in 2007, 1.1 (0.38) in 2012, *p* = 0.89).

Between 2007 and 2012, rates of NVNM consumption (past 12 months; [Table 1](#tab1){ref-type="table"}) declined among non-Hispanic White adults (83% to 79%) but increased among those identified as Hispanic (7% to 9%; *p*\'s \< 0.0001). Overall, the likelihood of NVNM use significantly increased by number of health conditions in both years ([Table 2](#tab2){ref-type="table"}; *p*\'s for trend ≤ 0.0001, not shown). In addition, NVNM users (past 12 months) spending under \$500 in out-of-pocket medical costs decreased (2007 and 2012: 35.0% and 31.3%, resp.) while NVNM users spending over \$3,000 increased (6.2% and 8.3%). This was also noted by an increase in likelihood of NVNM use by out-of-pocket costs for both years (*p*\'s for trend = 0.0001; not shown). Lastly, consumption of other natural products (i.e., vitamins/minerals) increased (93% to 96%) among all herbal users between time points.

3.1. Relation of FMS to Herbal Use {#sec3.1}
----------------------------------

Nearly 60% of those with FMS reported previous or current NVNM use; 42% indicated using NVNMs in the past 12 months, and 33% in the past 30 days ([Table 3](#tab3){ref-type="table"}). Approximately 3% of all NVNM users had FMS; this rate did not differ between years ([Table 4](#tab4){ref-type="table"}). In 2007, participants with FMS were 3.7 times as likely as those without FMS to use NVNMs for any length of time (OR = 3.7, 95% confidence interval (CI): 2.7, 5.0). After adjustment for demographic, lifestyle, and medical/health factors, those with FMS were 2.7 times as likely to report ever using NVNMs than those without FMS (adjusted odds ratio (AOR) = 2.7, (CI: 1.9, 3.8)). FMS showed a similarly strong positive association to recent NVNM use (12-month and 30-day AORs = 2.3 (CI: 1.5, 3.4) and 2.3 (CI: 1.6, 3.5), resp.). Likewise, FMS was significantly and positively associated with all NVNM use outcomes in 2012, although the magnitude of the associations was lower (2012 AORs: herbal use (ever) = 1.6 (CI: 1.3, 2.0); 12 months = 1.6 (CI: 1.2, 2.0); 30 days = 1.5 (CI: 1.2, 2.0)).

The magnitude of the association of NVNM use to FMS was significantly greater in those with 0-1 comorbid health conditions than in those with 2 or more health conditions (age-adjusted ORs, resp., = 4.7 (CI: 2.2, 9.8) versus 2.8 (CI: 2.0, 3.9; *p* for interaction = 0.008) in 2007; not shown). However, we found no evidence of a modifying effect of multiple comorbidities in 2012 or for gender in either year.

To our knowledge, this is the first large, population-based study to examine the relation of NVNM use to FMS; it is also among the first rigorous studies to investigate the relation of NVNM use to any chronic pain condition in a large sample \[[@B25], [@B29], [@B30], [@B36]\]. Relative to adults without FMS, those with FMS were significantly more likely to report using NVNMs at any time point (within the past 30 days or 12 months or ever) in both 2007 and 2012 survey years; the positive association of FMS to NVNM use remained highly significant even after controlling for a broad array of demographic, lifestyle, and health-related factors.

In our study, the majority of those with FMS indicated using NVNMs at some time point; one-third had used NVNMs in the past 30 days. Previous studies assessing herbal use in FMS reported widely varying rates among FMS patients, ranging from 43% (FMS = 434) to 78% (FMS = 90) \[[@B36], [@B37]\]. Reported rates among other chronic pain populations have been considerably lower, ranging from 6.8% in a sample of primary care patients using opioids \[[@B29]\] to 15% in a primary care patient population with chronic pain \[[@B30]\]. However, percentages given in prior studies were unweighted and may in part reflect differences in study populations and outcome definitions, rendering comparison with our findings challenging.

Prevalence of diagnosed FMS increased between 2007 and 2012 (1.3% to 1.7%). Despite lower rates than those appearing globally and in some US studies \[[@B1]--[@B3]\], this apparent rise in diagnosed FMS may be due in part to increased recognition of FMS by physicians following publication of the 2010 Preliminary ACR updated criteria for fibromyalgia.

In contrast, we found reported NVNM use among adults with FMS declined significantly from 2007 to 2012, paralleling the modest but significant reduction in overall NVNM use observed between these periods. However, the mean number of different combination NVNM supplements used by those with FMS did not differ between time points and averaged lower than that reported in a case-control study of North American women (*N* = 434 with FMS) \[[@B36]\]. In addition, both the observed decline in NVNM use among those with FMS and the positive but more modest association between NVNM use and FMS in 2012 compared to 2007 may also reflect increased availability of FDA-approved FMS medications following the 2007 NHIS survey administration. It also remains possible that both the increase in FMS diagnoses and decrease in odds of NVNM use for FMS over time are also in part the result of promotion for FMS drugs by pharmaceutical companies \[[@B38]\] and increased off-label prescription of other drugs for FMS, potentially including opioids \[[@B39], [@B40]\].

*Strengths and Limitations*. This investigation was the first study to assess the relation between NVNM use and FMS in a large US population. Strengths of our study include large, nationally representative samples, use of data from two time periods, and the availability of comprehensive information on NVNM use, as well as a broad array of demographic, lifestyle, health-related, and other potentially confounding factors. However, there were some limitations. Perhaps most important, the cross-sectional study design precluded determination of causal relationships. Ascertainment of NVNM use and medical history, including diagnosis of FMS, was reliant on self-report, raising the possibility of recall bias; however, potential underascertainment would likely bias our results toward the null, indicating more conservative estimates.

Although the NVNM use outcome mainly comprised of herbal dietary supplements and was assessed separately from many other nonherbal supplements in both NHIS data collection periods, the nonherbal products coenzyme Q-10, SAM-e, fish oil, and prebiotics/probiotics were included in our main NVNM outcome. Thus, our consideration of a broader NVNM outcome may be more appropriate than a specific herbal supplement use outcome, since reports of individual ingredients were not consistently available between years. There was inadequate capture of certain herbal products within the NVNM outcome. No data were available on consumption of herbal and green teas used for health purposes or on products not labelled (per NHIS requirements for inclusion) "dietary supplement," including home grown herbs, traditionally prepared herbal products, and bulk herbs/powders sometimes recommended (i.e., by nutritionists, natural foods purveyors) over widely available supplements due to quality and processing concerns. We did not have information on FMS severity or duration, and although the 2012 questionnaire differed from 2007, there were no differences with respect to assessment of fibromyalgia. Based on cognitive testing and input from expert panels, the definitions of certain modalities were modified in 2012 to reduce false-positive responses \[[@B34]\] which may have affected findings. However, these changes were relatively minor and were unlikely to affect our estimates, as these potential false-positives did not vary by disease status.

Given the high prevalence rates of those with FMS using NVNMs, and the strong, positive relationship of FMS to NVNM use which persisted in 2012 despite the availability of approved treatments, additional prospective research is warranted to confirm these findings, to further investigate the prevalence, patterns, and determinants of specific NVNM use in FMS, and to explore the safety and potential efficacy of NVNM products for this still poorly managed condition.

4. Conclusions {#sec4}
==============

In the first large cross-sectional study of two nationally representative samples of US adults, reported diagnosis of FMS was strongly and positively associated with NVNM use in both 2007 and 2012 after adjustment for demographic, lifestyle, and health factors. Rigorous prospective studies are needed to confirm these findings and to further explore the patterns, determinants, and potential efficacy of NVNM use in those with FMS.
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###### 

Demographic and lifestyle characteristics of 2007 and 2012 national US samples, stratified by NVNM use in the past 12 months, National Health Interview Survey.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic              2007 (*N* = 20,127)   *p*                2012 (*N* = 30,672)   *p*              Overall *p*^W^                                                                              
  --------------------------- --------------------- ------------------ --------------------- ---------------- ---------------- ---------------- ------------------ ---------- ---------------- ---------- -------------------
  Total                       3582 (19.1)           (18.4, 19.8)       16270972              16545 (80.9)                      5490 (18.5)      (17.8, 19.2)       16713004   25182 (72.4)                \<0.0001

  Age in years                                                                                                \<0.0001                                                                         \<0.0001   \<0.0001

   18--24                     269 (8.2)             (6.8, 9.6)         1332833               1884 (11.7)                       391 (7.4)        (6.3, 8.4)         1231081    2637 (11.1)                  

   25--44                     1169 (31.9)           (30.1, 33.7)       5193487               6195 (36.3)                       1775 (32.1)      (30.4, 33.7)       5358304    8879 (34.1)                  

   45--64                     1414 (39.8)           (37.9, 41.7)       6476821               5314 (32.3)                       2162 (39.1)      (37.5, 40.8)       6542615    8379 (33.1)                  

   65--75                     462 (12.6)            (11.4, 13.7)       2044193               1599 (9.5)                        741 (14.0)       (12.8, 15.1)       2332396    2777 (11.4)                  

   75+                        268 (7.5)             (6.5, 8.5)         1223638               1553 (10.2)                       421 (7.5)        (6.6, 8.4)         1248608    2510 (10.3)                  

   *Mean (SE)*                *49.06 (0.35)*        *(48.38, 49.75)*                         *47.09 (0.27)*   \<0.0001         *49.58 (0.33)*   *(48.93, 50.23)*              *48.24 (0.19)*   \<0.0001   0.2794

  Sex                                                                                                         0.0001                                                                           \<0.0001   \<0.0001

   Male                       1535 (43.2)           (41.3, 45.1)       7028291               7644 (47.8)                       2341 (42.8)      (41.1, 44.5)       7153927    11565 (47.3)                 

   Female                     2047 (56.8)           (54.9, 58.7)       9242681               8901 (52.2)                       3149 (57.2)      (55.5, 58.9)       9559077    13617 (52.7)                 

  Race/ethnicity                                                                                              \<0.0001                                                                         \<0.0001   \<0.0001

   Non-Hispanic White         2716 (82.9)           (81.7, 84.1)       13487880              9419 (69.6)                       3979 (78.8)      (77.5, 80.1)       13163299   14637 (67.4)                **∗** **∗** **∗**

   Non-Hispanic Black         329 (6.9)             (6.0, 7.8)         1121133               2812 (13.5)                       513 (7.6)        (6.7, 8.4)         1266927    4058 (13.3)                  

   Hispanic                   360 (6.7)             (5.9, 7.5)         1091895               3358 (12.8)                       622 (9.0)        (8.1, 9.8)         1496127    4796 (14.4)                 **∗** **∗** **∗**

   Asian                      99 (1.8)              (1.4, 2.2)         297318                547 (2.3)                         196 (2.6)        (2.2, 3.0)         438850     975 (2.9)                    

   Other Race/ethnicity       78 (1.7)              (1.3, 2.0)         272746                409 (1.8)                         180 (2.1)        (1.7, 2.4)         347801     716 (2.1)                    

  Marital status                                                                                              0.088                                                                            0.009      \<0.0001

   Married/\                  1903 (52.0)           (50.0, 53.9)       8453944               8507 (51.4)                       2865 (52.1)      (50.2, 53.9)       8703339    12354 (49.4)                 
  Cohabitating                                                                                                                                                                                            

   Never married              710 (21.0)            (19.2, 22.7)       3411156               3800 (23.1)                       1206 (22.8)      (21.2, 24.4)       3813588    6184 (24.7)                  

   Divorced/sep/\             969 (27.1)            (25.5, 28.7)       4405872               4238 (25.6)                       1419 (25.1)      (23.7, 26.5)       4196077    6644 (25.9)                  
  widow                                                                                                                                                                                                   

  Education                                                                                                   \<0.0001                                                                         \<0.0001   \<0.0001

   \<12th grade               272 (7.0)             (6.1, 7.8)         1131795               3307 (16.5)                       417 (6.4)        (5.7, 7.2)         1076502    4420 (15.1)                  

   HS/GED                     808 (22.3)            (20.7, 23.8)       3624376               4830 (29.6)                       1043 (18.4)      (17.2, 19.6)       3078409    6860 (26.8)                 **∗** **∗** **∗**

   Tech training/\            1185 (33.4)           (31.6, 35.2)       5436406               4527 (28.5)                       1924 (35.3)      (33.6, 36.9)       5896361    7548 (30.7)                  
  some college                                                                                                                                                                                            

   ≥Bachelor\'s degree        1317 (37.4)           (35.4, 39.3)       6078395               3881 (25.4)                       2106 (39.9)      (38.1, 41.6)       6661732    6354 (27.4)                  

  Employment                                                                                                  \<0.0001                                                                         \<0.0001   \<0.0001

   Employed for pay           2189 (61.6)           (59.8, 63.3)       10016152              9818 (59.5)                       3301 (60.2)      (58.5, 61.9)       10065089   13857 (55.4)                 

   Employed but not for pay   162 (4.8)             (4.0, 5.6)         784425                465 (3.1)                         227 (4.3)        (3.7, 5.0)         725979     703 (3.0)                    

   Unemployed                 1231 (33.6)           (31.9, 35.3)       5470395               6262 (37.4)                       1962 (35.4)      (33.7, 37.1)       5921936    10622 (41.7)                

  Income                                                                                                      \<0.0001                                                                         \<0.0001   \<0.0001

   \$1--\$24,999              820 (23.4)            (21.8, 25.1)       3809168               3710 (22.2)                       1186 (21.0)      (19.8, 22.3)       3512363    5670 (21.6)                  

   \$25,000--\$44,999         576 (15.7)            (14.3, 17.1)       2553714               2545 (15.9)                       894 (16.3)       (15.1, 17.5)       2727946    3675 (14.5)                  

   \$45,000--\$74,999         478 (13.5)            (12.2, 14.9)       2203952               1643 (10.6)                       803 (14.9)       (13.7, 16.0)       2490180    2727 (11.5)                  

   \$75,000 and over          341 (10.0)            (8.8, 11.1)        1622926               858 (5.6)                         583 (11.4)       (10.4, 12.5)       1912903    1683 (7.5)                   

   Do not know                129 (3.6)             (3.0, 4.2)         578665                944 (5.3)                         189 (3.2)        (2.6, 3.8)         538020     1103 (4.3)                   

   Missing                    1238 (33.8)           (31.9, 35.7)       5502547               6845 (40.4)                       1835 (33.1)      (31.6, 34.6)       5531592    10324 (40.5)                 

  Geographic location                                                                                         \<0.0001                                                                         \<0.0001   \<0.0001

   Northeast                  541 (15.5)            (13.8, 17.2)       2526830               2783 (17.4)                       762 (13.9)       (12.5, 15.3)       2324064    4325 (18.3)                  

   Midwest                    850 (25.6)            (23.1, 28.1)       4161206               3642 (25.0)                       1230 (26.2)      (24.2, 28.1)       4374539    5173 (23.3)                  

   South                      1190 (32.2)           (29.7, 34.7)       5232720               6337 (37.8)                       1506 (29.2)      (26.8, 31.7)       4886374    9683 (38.9)                  

   West                       1001 (26.7)           (24.6, 28.9)       4350216               3783 (19.8)                       1992 (30.7)      (28.6, 32.7)       5128027    6001 (19.6)                  

  Place of birth                                                                                                                                                                                          \<0.0001

   US born                    3164 (91.0)           (90.1, 91.9)       14807161              13116 (85.4)     \<0.0001         4791 (89.8)      (88.9, 90.7)       15010846   20112 (83.5)     \<0.0001    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*. Column percentages shown; ^*∗*^adjusted for age, sex, and race/ethnicity based on 2000 Census data; ^*∗∗*^adjusted for age, sex, and race/ethnicity based on 2010 Census data; ^**∗∗∗**^significant changes between 2007 and 2012 indicated by nonoverlapping weighted population confidence intervals; ^W^*p* values obtained by comparing weighted estimates; note: significant changes between datasets with differing weighting schemes indicated by nonoverlapping weighted population confidence intervals as *∗∗∗*.

###### 

Medical care/health characteristics of 2007 and 2012 national US samples, stratified by NVNM use in the past 12 months, National Health Interview Survey.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                                  2007 (*N* = 20,127)   *p*                  2012 (*N* = 30,672)   *p*               Overall *p*^W^                                                                                  
  --------------------------------------------------------------- --------------------- -------------------- --------------------- ----------------- ---------------- ----------------- -------------------- ---------- ----------------- ---------- ------------------------
  Insurance status                                                                                                                                                                                                                                    

   Uninsured                                                      505 (13.4)            (12.4, 14.5)         2185136               2999 (16.2)       \<0.0001         790 (13.0)        (12.0, 13.9)         2168607    4705 (16.5)       \<0.0001   \<0.0001

   Medicaid                                                       155 (4.0)             (3.3, 4.6)           645744                1510 (7.6)        \<0.0001         287 (4.4)         (5.2, 10.5)          735478     2736 (9.3)        \<0.0001   **\<0.0001** ^**∗∗∗**^

   Medicare                                                       786 (21.6)            (20.0, 23.2)         3519561               3466 (21.7)       0.623            1277 (23.3)       (21.8, 24.8)         3892141    5922 (23.9)       0.451      \<0.0001

   Disability                                                     63 (2.0)              (1.3, 2.7)           321398                165 (0.96)        \<0.0001         111 (2.1)         (1.7, 2.5)           346117     258 (1.1)         \<0.0001   \<0.0001

   Private insurance                                              2537 (72.6)           (70.9, 74.3)         11813273              10211 (65.3)      \<0.0001         3736 (70.2)       (68.7, 71.8)         11739270   14238 (60.2)      \<0.0001   \<0.0001

  Out of pocket costs, annual^\$^                                                                                                                    \<0.0001                                                                             \<0.0001   \<0.0001

   None                                                           286 (7.8)             (6.8, 8.8)           1272433               2155 (11.7)                        483 (8.1)         (7.3, 9.0)           1358939    3811 (13.9)                   

   \<\$500                                                        1249 (35.0)           (33.3, 36.8)         5700791               6719 (39.6)                        1780 (31.3)       (29.7, 32.9)         5230362    9593 (37.3)                  **∗** **∗** **∗**

   \$500--\$1999                                                  1236 (34.1)           (32.4, 35.8)         5549126               4755 (29.5)                        1809 (33.8)       (32.4, 35.1)         5641914    6938 (28.3)                   

   \$2000--\$2999                                                 333 (9.3)             (8.3, 10.3)          1512573               1151 (7.7)                         554 (10.3)        (9.3, 11.3)          1717635    2025 (8.7)                    

   \$3000--\$4999                                                 217 (6.2)             (5.3, 7.1)           1008834               691 (4.5)                          420 (8.3)         (7.5, 9.1)           1391128    1237 (5.1)                   **∗** **∗** **∗**

   \$5000+                                                        222 (6.4)             (5.6, 7.2)           1039327               635 (4.1)                          396 (7.3)         (6.5, 8.1)           1219938    1180 (5.1)                    

   Do not know                                                    39 (1.2)              (0.74, 1.6)          187888                439 (2.9)                          48 (0.9)          (0.63, 1.2)          153088     398 (1.6)                     

  Delayed care because they could not afford/worried about cost   621 (17.6)            (16.2, 19.0)         2867318               1947 (12.0)       \<0.0001         964 (16.7)        (15.6, 17.9)         2794500    3478 (13.2)       \<0.0001   \<0.0001

  Perceived health status                                                                                                                            0.001                                                                                0.001      \<0.0001

   Excellent/very good/good                                       3133 (87.7)           (86.6, 88.9)         14272846              14162 (86.3)                       4849 (89.7)       (88.8, 90.6)         14987051   21383 (86.2)                  

   Fair                                                           363 (10.0)            (9.0, 11.1)          1632026               1781 (10.1)                        505 (8.1)         (7.3, 8.9)           1347889    2942 (10.7)                  **∗** **∗** **∗**

   Poor                                                           86 (2.3)              (1.7, 2.8)           366100                602 (3.6)                          136 (14.0)        (1.8, 2.7)           378064     857 (86.0)                    

  Physical activity^R^                                                                                                                                                                                                                                

   None                                                           915 (24.6)            (22.9, 26.3)         4001744               7428 (42.2)       \<0.0001         1078 (18.9)       (17.7, 20.1)         3158655    9136 (34.8)       \<0.0001   **\<0.0001** ^**∗∗∗**^

   Low/moderate                                                   2298 (65.3)           (63.3, 67.3)         10629710              7504 (47.5)       \<0.0001         3837 (70.8)       (69.5, 72.2)         11841154   13429 (54.8)      \<0.0001   **\<0.0001** ^**∗∗∗**^

   High                                                           1613 (46.5)           (44.5, 48.5)         7571196               5164 (33.8)       \<0.0001         2924 (54.7)       (53.0, 56.3)         9136857    9817 (40.6)       \<0.0001   **\<0.0001** ^**∗∗∗**^

   *Mean (SE) (weekly) (min)*                                     *283.09 (10.23)*      *(262.96, 303.22)*                         *198.45 (6.00)*   \<0.0001         *325.00 (9.77)*   *(305.77, 344.24)*              *239.65 (4.63)*   \<0.0001   **0.003** ^**∗∗∗**^

  Body mass index (BMI)                                                                                                                              0.016                                                                                0.031      \<0.0001

   \<24.9                                                         1384 (39.0)           (37.3, 40.8)         6348273               6243 (38.7)                        2057 (38.6)       (37.0, 40.1)         6448785    9039 (36.3)                   

   25--29.9                                                       1246 (34.5)           (32.7, 36.2)         5605830               5875 (35.4)                        1916 (34.4)       (32.9, 36.0)         5757553    8717 (34.8)                   

   30--35                                                         614 (17.2)            (15.8, 18.6)         2793014               2731 (16.1)                        903 (16.3)        (15.1, 17.4)         2718245    4425 (17.3)                   

   35+                                                            338 (9.4)             (8.3, 10.5)          1523855               1696 (9.9)                         614 (10.7)        (9.8, 11.6)          1788421    3001 (11.6)                   

   *Mean (SE)*                                                    *27.37 (0.11)*        *(27.15, 27.60)*                           *27.35 (0.56)*    0.887            *27.54 (0.09)*    *(27.36, 27.72)*                *27.77 (0.05)*    0.024      0.2305

  Tobacco use                                                                                                                                        \<0.0001                                                                             \<0.0001   \<0.0001

   Never                                                          1894 (51.2)           (49.2, 53.2)         8330263               9977 (57.6)                        3114 (56.3)       (54.8, 57.9)         9413789    14939 (58.3)                 **∗** **∗** **∗**

   Former                                                         1067 (30.3)           (28.7, 31.9)         4930987               3292 (21.2)                        1539 (28.6)       (27.3, 30.0)         4788193    5281 (22.0)                   

   Current                                                        621 (18.5)            (16.7, 20.3)         3009722               3276 (21.2)                        837 (15.0)        (13.8, 16.2)         2511022    4962 (19.6)                  **∗** **∗** **∗**

  Alcohol use                                                                                                                                        \<0.0001                                                                             \<0.0001   \<0.0001

   None                                                           1006 (26.7)           (25.1, 28.4)         4349888               6958 (39.0)                        1454 (24.0)       (22.5, 25.5)         4012831    9897 (36.6)                   

   Light                                                          1740 (47.9)           (46.1, 49.7)         7794610               6609 (41.0)                        2662 (49.6)       (48.0, 51.3)         8292892    10426 (42.7)                  

   Moderate to heavy                                              836 (25.4)            (23.6, 27.1)         4126474               2978 (19.9)                        1374 (26.4)       (24.9, 27.9)         15263475   4859 (20.7)                   

  Substance abuse                                                 30 (0.81)             (0.52, 1.1)          132414                96 (0.62)         0.157            62 (1.3)          (0.89, 1.6)          210988     164 (0.66)        0.0003     \<0.0001

  Comorbidity index^a^                                                                                                                                                                                                                                

   None                                                           918 (25.6)            (23.9, 27.3)         4164042               6532 (38.4)       \<0.0001         1035 (18.7)       (17.5, 19.8)         3117059    7588 (29.8)       \<0.0001   **0.0001** ^**∗∗∗**^

   One                                                            912 (26.0)            (24.4, 27.5)         4225414               3846 (23.7)                        1218 (22.3)       (20.9, 23.6)         3721577    5717 (22.9)                  **∗** **∗** **∗**

   Two                                                            662 (18.4)            (16.9, 19.8)         2987313               2488 (15.5)                        1083 (19.6)       (18.4, 20.8)         3272605    4243 (17.2)                   

   ≥Three                                                         1090 (30.1)           (28.4, 31.7)         4894203               3679 (22.4)                        2154 (39.5)       (37.8, 41.2)         6601763    7634 (30.2)                  **∗** **∗** **∗**

   *Mean (SE)*                                                    *1.83 (0.03)*         *(1.77, 1.90)*                             *1.45 (0.02)*     \<0.0001         *2.23 (0.03)*     *(2.17, 2.29)*                  *1.84 (0.02)*     \<0.0001   **\<0.0001** ^**∗∗∗**^

  *Chronic health conditions*                                                                                                                                                                                                                         

   Diabetes                                                       314 (8.2)             (7.2, 9.1)           1331587               1633 (9.4)        0.021            596 (10.2)        (9.3, 11.2)          1709992    2965 (11.2)       0.106      **\<0.0001** ^**∗∗∗**^

   Kidney disease                                                 57 (1.6)              (1.2, 2.1)           263373                289 (1.6)         0.713            91 (1.5)          (1.2, 1.8)           250872     506 (1.9)         0.047      \<0.0001

   GI disease^aa^                                                 590 (16.9)            (15.5, 18.3)         2752405               1696 (10.8)       \<0.0001         2186 (40.4)       (38.9, 41.9)         6744109    7468 (29.9)       \<0.0001   **\<0.0001** ^**∗∗∗**^

   Chronic resp. conditions^b^                                    615 (16.9)            (15.6, 18.2)         2745606               2144 (13.4)       \<0.0001         985 (18.0)        (16.8, 19.3)         3015703    3762 (15.1)       \<0.0001   \<0.0001

   CVD^c^                                                         257 (7.0)             (6.1, 7.9)           1142025               1078 (6.8)        0.607            393 (7.1)         (6.3, 7.9)           1186819    1829 (7.3)        0.621      \<0.0001

   Hypertension                                                   1136 (31.1)           (29.4, 32.9)         5064154               4764 (28.7)       0.017            1856 (33.4)       (31.8, 35.0)         5582424    8168 (32.2)       0.165      \<0.0001

   Dyslipidemia                                                   1159 (32.2)           (30.5, 34.0)         5246236               3977 (24.6)       \<0.0001         1881 (33.9)       (32.2, 35.6)         5659527    6628 (26.8)       \<0.0001   \<0.0001

   Liver disease                                                  54 (1.5)              (1.1, 1.9)           244387                198 (1.2)         0.138            91 (1.6)          (1.2, 2.0)           271510     348 (1.3)         0.146      \<0.0001

   Chronic pain conditions^d^                                     1836 (51.6)           (49.8, 53.3)         8390744               5940 (36.9)       \<0.0001         3018 (55.2)       (53.9, 56.9)         9263106    9943 (39.9)       \<0.0001   **\<0.0001** ^**∗∗∗**^

   Mental health conditions^e^                                    832 (23.8)            (22.1, 25.6)         3874783               2623 (16.0)       \<0.0001         1674 (30.4)       (28.9, 31.9)         5084683    5854 (22.9)       \<0.0001   \<0.0001

   Insomnia                                                       948 (26.9)            (25.2, 28.7)         4383811               2885 (17.8)       \<0.0001         1488 (26.8)       (25.4, 28.2)         4472612    4728 (18.8)       \<0.0001   \<0.0001

   History of cancer                                              355 (10.1)            (9.0, 11.2)          1638188               1101 (7.4)        \<0.0001         569 (10.7)        (9.7, 11.7)          1792043    2039 (8.6)        \<0.0001   \<0.0001

  Use of other complementary health approaches                    3539 (98.9)           (98.6, 99.3)         16094998              14150 (86.2)      \<0.0001         5357 (97.9)       (97.5, 98.4)         16369136   17689 (72.1)      \<0.0001   **\<0.0001** ^**∗∗∗**^

   Other natural products^f^                                      3331 (93.4)           (92.4, 94.4)         15192940              10243 (64.4)      \<0.0001         5215 (95.5)       (94.9, 96.2)         15965914   15806 (64.5)      \<0.0001   **\<0.0001** ^**∗∗∗**^

   Mind-body^g^                                                   1870 (53.2)           (51.5, 55.0)         8659604               3621 (23.6)       \<0.0001         2094 (39.7)       (38.0, 41.4)         6633294    3290 (13.9)       \<0.0001   **\<0.0001** ^**∗∗∗**^

   Manipulative/\                                                 2034 (58.4)           (56.5, 60.3)         9496114               4144 (27.1)       \<0.0001         2783 (51.7)       (50.0, 53.4)         8634942    6075 (25.3)       \<0.0001   **\<0.0001** ^**∗∗∗**^
  bodywork^h^                                                                                                                                                                                                                                        

   Energy healing/Reiki                                           218 (6.1)             (5.2, 7.0)           997157                137 (0.89)        \<0.0001         240 (4.5)         (3.8, 5.1)           747014     123 (0.47)        \<0.0001   **\<0.0001** ^**∗∗∗**^

   spiritual practices^i^                                         2334 (64.6)           (62.7, 66.5)         10512222              9637 (56.5)       \<0.0001         643 (12.5)        (11.4, 13.5)         2081886    718 (2.9)         \<0.0001   **\<0.0001** ^**∗∗∗**^

   Alternative systems^k^                                         858 (23.8)            (22.1, 25.5)         3867268               1136 (6.9)        \<0.0001         1037 (19.0)       (17.8, 20.2)         3180077    1231 (4.9)        \<0.0001   **\<0.0001** ^**∗∗∗**^
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*. Column percentages shown; ^*∗*^adjusted for age, sex, and race/ethnicity based on 2000 Census data; ^*∗∗*^adjusted for age, sex, and race/ethnicity based on 2010 Census data; ^**∗∗∗**^significant changes between 2007 and 2012 indicated by nonoverlapping weighted population confidence intervals; ^W^*p* values obtained by comparing weighted estimates; note: significant changes between datasets with differing weighting schemes indicated by nonoverlapping weighted population confidence intervals as *∗∗∗*; ^\$^family costs aside from deductibles, premiums, copays; ^R^defined as ≥10 min. increments; ^a^including diabetes, kidney disease, gastrointestinal disorder (including ulcer and/or abdominal pain, digestive allergy, and heartburn), respiratory conditions (asthma, emphysema, and/or chronic bronchitis), dyslipidemia, liver condition, rheumatoid arthritis, CVD, hypertension, nonspecific arthritis, gout, migraines, mental health condition; ^aa^including bowel conditions and ulcers (2007); past 12 months: abdominal pain, digestive allergy, heartburn, and ever having ulcer (2012); ^b^asthma, emphysema, and/or chronic bronchitis; ^c^myocardial infarction, heart disease, angina pectoris; ^d^migraines (past 3 months), nonspecific arthritis, gout, nonspecific joint pain for 3+ months, rheumatoid arthritis; ^e^depression, bipolar disorder, phobias, often anxious (past year); ^f^supplements other than NVNMs, including vitamins/minerals, probiotics (past 30 days), fish oil (past 30 days), chelation therapies; ^g^Tai Chi/Qi Gong, yoga, guided imagery, progressive relaxation, deep breathing exercises, meditation (singular term "meditation" used in 2007; expanded in 2012 to include mantra and mindfulness meditation), mindfulness-based stress reduction and cognitive therapy (2012), stress-management class (2007), biofeedback, hypnosis; ^h^practitioner-based massage (ever), chiropractic/osteopathic manipulation, Sobador visit; ^i^prayed for one\'s own health (2007) or centering prayer/contemplative meditation (2012); and/or visit with Espiritista (2007 only), Curandero, Shaman, and/or native American healer; ^k^acupuncture, Ayurveda, homeopathy, and naturopathy.

###### 

NVNM use in two nationally representative samples of adults with diagnosed fibromyalgia, National Health Interview Survey (NHIS 2007 *N* = 221 (1.3%^*∗*C1^) versus NHIS 2012 *N* = 524 (1.7%^*∗∗*C2^)).

  Characteristic                                       2007            2012            Overall *p*^W^                                             
  ---------------------------------------------------- --------------- --------------- ---------------- --------------- --------------- --------- ------------------------
  NVNM use ever                                                                                                                                   **\<0.0001** ^**∗∗∗**^
   Yes                                                 114 (57.1)      (49.3, 64.9)    624881           204 (40.6)      (35.3, 45.8)    633029     
   No                                                  107 (42.9)      (35.1, 50.7)    469162           320 (59.4)      (54.2, 64.7)    927192     
  NVNM use in past 12 months                                                                                                                      \<0.0001
   Yes                                                 82 (41.7)       (33.3, 50.2)    456477           157 (31.2)      (26.1, 36.4)    487362     
   No                                                  139 (58.3)      (49.8, 66.7)    637566           367 (68.8)      (63.6, 73.9)    1072859    
  NVNM use in past 30 days                                                                                                                        \<0.0001
   Yes                                                 62 (32.7)       (24.6, 40.9)    358265           126 (24.5)      (19.9, 29.1)    382285     
   No                                                  159 (67.3)      (59.1, 75.4)    735778           398 (75.5)      (70.9, 80.1)    1177936    
  Number of different NVNM supps in past 30 days^tt^                                                                                               
   *(Mean (SE))*                                       *0.99 (0.20)*   *(0.60, 1.4)*                    *1.07 (0.38)*   *(0.32, 1.8)*             0.894
  Physician disclosure of NVNM^d^                                                                                                                 \<0.0001
   Yes                                                 50 (64.6)       (53.1, 76.1)    294988           51 (71.4)       (59.0, 83.9)    140681     
   No                                                  32 (35.4)       (23.9, 46.9)    161489           15 (28.6)       (16.1, 41.0)    56221      

*Note*. Total sample with fibromyalgia is percentage denominator; ^*∗*^adjusted for age, sex, and race/ethnicity based on 2000 Census data; ^*∗∗*^adjusted for age, sex, and race/ethnicity based on 2010 Census data; ^*∗***∗∗**^significant changes between 2007 and 2012 indicated by nonoverlapping weighted population confidence intervals; ^W^*p* values obtained by comparing weighted estimates; note: significant changes between datasets with differing weighting schemes indicated by nonoverlapping weighted population confidence intervals as *∗∗∗*; ^tt^among NVNM users with fibromyalgia; including combination NVNM supplement; ^d^within past 30 days (*N* = 66; 2007); only disclosure of top therapy assessed within past 12 months (2012); ^C1^(95% CI: 1.1, 1.5); ^C2^(95% CI: 1.6, 1.9).

###### 

Association of NVNM use to self-reported fibromyalgia diagnosis in two nationally representative samples of adults, National Health Interview Survey (NHIS 2007, *N* = 20,127; and 2012, *N* = 30,672).

                                   *N* (%)       95% CI         Unadjusted odds ratio (95% CI)   *p*            Odds ratio adjusted for demographics and related factors^*∗*^ (95% CI)   *p*            Odds ratio adjusted for demographics, lifestyle, and related factors^*¥*^ (95% CI)   *p*            Odds ratio adjusted for demographics, lifestyle, and related factors + comorbidity^t^ (95% CI)   *p*
  -------------------------------- ------------- -------------- -------------------------------- -------------- ------------------------------------------------------------------------ -------------- ------------------------------------------------------------------------------------ -------------- ------------------------------------------------------------------------------------------------ --------------
  *NHIS 2007*                                                                                                                                                                                                                                                                                                                                                                                                 
  NVNM use in the last 30 days                                                                                                                                                                                                                                                                                                                                                                                
   Fibromyalgia                                                                                                                                                                                                                                                                                                                                                                                               
    Yes                            62 (3.0)      (2.1, 3.9)     3.07 (2.12, 4.45)                **\<0.0001**   2.36 (1.59, 3.51)                                                        **\<0.0001**   2.54 (1.69, 3.83)                                                                    **\<0.0001**   2.34 (1.55, 3.52)                                                                                **\<0.0001**
    No                             2561 (97.0)   (96.1, 97.9)   1.00 (reference)                                1.00 (reference)                                                                        1.00 (reference)                                                                                    1.00 (reference)                                                                                  
  NVNM use in the last 12 months                                                                                                                                                                                                                                                                                                                                                                              
   Fibromyalgia                                                                                                                                                                                                                                                                                                                                                                                               
    Yes                            82 (2.8)      (2.0, 3.6)     3.09 (2.19, 4.37)                **\<0.0001**   2.34 (1.58, 3.47)                                                        **\<0.0001**   2.48 (1.67, 3.71)                                                                    **\<0.0001**   2.25 (1.51, 3.35)                                                                                **\<0.0001**
    No                             3500 (97.2)   (96.4, 98.0)   1.00 (reference)                                1.00 (reference)                                                                        1.00 (reference)                                                                                    1.00 (reference)                                                                                  
  NVNM use ever                                                                                                                                                                                                                                                                                                                                                                                               
   Fibromyalgia                                                                                                                                                                                                                                                                                                                                                                                               
    Yes                            114 (2.7)     (2.1, 3.3)     3.66 (2.66, 5.03)                **\<0.0001**   2.85 (2.02, 4.02)                                                        **\<0.0001**   3.01 (2.13, 4.25)                                                                    **\<0.0001**   2.66 (1.85, 3.82)                                                                                **\<0.0001**
    No                             4943 (97.3)   (96.7, 97.9)   1.00 (reference)                                1.00 (reference)                                                                        1.00 (reference)                                                                                    1.00 (reference)                                                                                  
  *NHIS 2012*                                                                                                                                                                                                                                                                                                                                                                                                 
  NVNM use in the last 30 days                                                                                                                                                                                                                                                                                                                                                                                
   Fibromyalgia                                                                                                                                                                                                                                                                                                                                                                                               
    Yes                            126 (3.0)     (2.4, 3.6)     2.04 (1.59, 2.61)                **\<0.0001**   1.65 (1.27, 2.14)                                                        **0.0002**     1.72 (1.33, 2.24)                                                                    **\<0.0001**   1.51 (1.15, 2.00)                                                                                **0.003**
    No                             3994 (97.0)   (96.4, 97.6)   1.00 (reference)                                1.00 (reference)                                                                        1.00 (reference)                                                                                    1.00 (reference)                                                                                  
  NVNM use in the last 12 months                                                                                                                                                                                                                                                                                                                                                                              
   Fibromyalgia                                                                                                                                                                                                                                                                                                                                                                                               
    Yes                            157 (2.9)     (2.4, 3.4)     2.03 (1.62, 2.56)                **\<0.0001**   1.72 (1.34, 2.20)                                                        **\<0.0001**   1.82 (1.42, 2.33)                                                                    **\<0.0001**   1.57 (1.21, 2.04)                                                                                **0.0007**
    No                             5333 (97.1)   (96.6, 97.6)   1.00 (reference)                                1.00 (reference)                                                                        1.00 (reference)                                                                                    1.00 (reference)                                                                                  
  NVNM use ever                                                                                                                                                                                                                                                                                                                                                                                               
   Fibromyalgia                                                                                                                                                                                                                                                                                                                                                                                               
    Yes                            204 (2.9)     (2.4, 3.3)     2.17 (1.75, 2.69)                **\<0.0001**   1.84 (1.47, 2.32)                                                        **\<0.0001**   1.92 (1.52, 2.42)                                                                    **\<0.0001**   1.59 (1.25, 2.03)                                                                                **0.0002**
    No                             7034 (97.1)   (96.7, 97.6)   1.00 (reference)                                1.00 (reference)                                                                        1.00 (reference)                                                                                    1.00 (reference)                                                                                  

Boldface indicates statistical significance at *p* ≤ 0.05; ^*∗*^adjusted for age, sex, race, education, employment, income, geographic location of birth, insurance status (Medicaid, disability, and private), out-of-pocket medical expenses, delayed access to care due to cost, and region (2007); additionally, marital status (2012); ^*¥*^additionally adjusted for smoking status, alcohol use, exercise, and BMI (2007); and substance abuse (2012); ^t^health conditions include diabetes, kidney disease, gastrointestinal disorder (including ulcer), respiratory conditions, dyslipidemia, liver condition, rheumatoid arthritis, CVD, hypertension, arthritis, gout, migraines, and mental health condition; and self-reported health status.

[^1]: Academic Editor: Simon Stebbings
